LSD molecule:

Image from PubChem

LSD Clinical Trials

A randomised, double-blind, placebo-controlled trial of repeated microdoses of lysergic acid diethylamide (LSD) in healthy volunteers

To see complete record on, please visit this link

Id: ACTRN12621000436875

Organisation Name: The University of Auckland

Overal Status: Not yet recruiting

Start Date: 01/05/2021

Brief Summary: “Microdosing” refers to repeated administration of psychedelics such as LSD or psilocybin in doses below the threshold for overtly altering perception. There is a growing microdosing subculture and grey literature suggesting that this practice can enhance creativity and productivity, improve mood and favourably modify personality traits. These claimed effects are similar to those observed in clinical studies, in which participants receive much larger, perception-altering doses of LSD or psilocybin. However, there are as yet no controlled, scientific studies of the psychological or physiological effects of repeated psychedelic home-self-administered microdosing. Given the powerful nature of placebo and expectancy effects on self-reports, controlled trials are required to objectively evaluate the effects of microdoses of psychedelic drugs in humans. In this study, we will conduct a randomised controlled trial of repeated microdoses of LSD under schedules similar to those suggested in the grey literature. 80 healthy volunteers will be randomised to receive repeated doses of either inactive placebo or LSD (10 µg oral) under double-blind conditions in a parallel groups design. A variety of physiological and psychological measures will be recorded at baseline and after completion of each of a six-week dosing regimen. Measures will include a validated personality scale and tests of creativity. Electroencephalography will be used to directly measure brain function in each participant before and after treatment. Our results will enable a rigorous evaluation of the purported benefits of psychedelic microdosing and will be relevant to the question of whether microdosing may be a viable alternative treatment regimen for depression, where full psychedelic doses are currently being investigated in clinical trials.

  • New Zealand

Total execution time in seconds: 0.31460499763489